Prof. Dr. rer. nat. Lothar Elling is a University Professor and director at the Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Germany. His research focuses on biomaterials, glycoengineering, and enzymatic synthesis of carbohydrates and glycoconjugates. Institution: RWTH Aachen University Research Unit: Helmholtz Institute for Biomedical Engineering Academic Rank: Full Professor Prof. Elling's research interests include: Glycoengineering of biomaterials Enzymatic synthesis of glycans Glycosyltransferase immobilization Glycan-protein interactions Biocatalytic cascade reactions Biomedical applications of glycomaterials His recent publications demonstrate strong expertise in: - Automated enzymatic glycan synthesis - Multi-enzyme cascade systems for nucleotide sugar production - Glycosyltransferase engineering - Galectin-targeted glycomaterials - Microgel-based biosensors
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Dr. Ed E. Moret is an Associate Professor of Computational Medicinal Chemistry at Utrecht University, where he serves as Managing Director of the Utrecht Institute for Pharmaceutical Sciences. He is a member of the Departmental Executive Board and Chair of the Board of Examiners of the School of Pharmacy. His academic career spans over three decades with significant contributions to pharmaceutical sciences. Utrecht University, Utrecht Institute for Pharmaceutical Sciences School of Pharmacy, Department of Chemical Biology and Drug Discovery Managing Director since January 2010 Dr. Moret's educational background includes completing Gymnasium-b at Gymnasium Camphusianum in Gorinchem in 1979, followed by pharmacy studies at Utrecht University until 1988. He earned his PhD in 1993 with research on calculations and simulations of DNA-alkylating cytostatics under supervision of Prof. L.H.M. Janssen and Prof. J.P.A.E. Tollenaere. He also conducted postdoctoral research at the Scripps Research Institute with Prof. A.J. Olson. His primary research interests focus on molecular recognition, particularly in auto-immune diseases, with expertise spanning computational medicinal chemistry, computer-aided drug discovery, cheminformatics, and bioinformatics. Dr. Moret's work bridges the gap between theoretical calculations and experimental validation in drug design. His research portfolio demonstrates a consistent trajectory from fundamental molecular interactions to applied drug discovery, with particular emphasis on enzyme inhibitors, carbohydrate-protein interactions, and molecular recognition processes. Analysis of his publication record reveals a strong focus on structure-based drug design, with significant contributions to the development of inhibitors for enzymes like β-glucocerebrosidase, NNMT, and neuraminidase. His work spans multiple therapeutic areas including lysosomal storage disorders, cancer metabolism, and infectious diseases. The interdisciplinary nature of his research is evident in the integration of computational approaches with experimental validation across biochemistry, pharmacology, and medicinal chemistry. Teacher of the Year (awarded three times by Pharmacy students) Member of editorial boards for Medicines and Conceptuur journals Secretary of Board of FIGON (2016) Secretary of Raad voor de Farmaceutische Wetenschappen (2024) Member of Board of Stichting Farmaceutische Erfgoed (2024) Dr. Moret has been actively involved in educational innovation, developing and coordinating the master's programme Drug Innovation, the profile Drug Regulatory Sciences, and the Honours programme Pharmaceutical Sciences. He has taught courses for pharmacy, chemistry, UCU and medical sciences students, as well as PhD courses in bioinformatics and computer-aided drug discovery. His educational contributions include developing an inquiry-based elective course on drug discovery, for which he published educational research. He holds BKO and SKO teaching qualifications and participated in the Centre of Excellence in University Teaching program. As Managing Director of the Utrecht Institute for Pharmaceutical Sciences, Dr. Moret leads research initiatives across chemical biology, drug discovery, and pharmaceutical sciences. His leadership extends to multiple advisory and editorial roles within the pharmaceutical research community, reflecting his significant contributions to both academic and professional spheres of pharmaceutical sciences.
Sonja Schelhaas is a researcher affiliated with the European Institute for Molecular Imaging (EIMI) at the University of Münster. Her work focuses on molecular imaging technologies, particularly in oncology and neurological contexts. PhD in Medical Biochemistry (2007-2010) Postdoc at EIMI since 2010 Research Fellow in Anaesthesiology (2005-2006) Her research spans: PET tracer development for ion channels Molecular imaging of tumor microenvironments Applications of small animal PET in disease models Bacterial and inflammatory imaging Radiochemistry and multimodal imaging techniques Epigenetic regulation in cancer Recent publications highlight her contributions to: P2X4 receptor antagonists for PET tracers KCa31 channel imaging in cancer Bacterial detection via radiolabeled compounds FLT PET for tumor proliferation analysis Neurogenesis and blood-brain barrier studies PEGylated nanoparticle characterization Schelhaas has collaborated extensively in preclinical imaging projects, contributing to cancer research, infection monitoring, and neurodegenerative disease modeling. Her work appears in journals like Journal of Medical Chemistry , Cancer Research , and Molecular Imaging and Biology .
Robert J. Doerksen is Professor of Medicinal Chemistry in the Department of BioMolecular Sciences at the University of Mississippi School of Pharmacy , Associate Dean of the Graduate School , and Research Professor in the Research Institute of Pharmaceutical Sciences . Since 2004 he has combined computational chemistry with experimental collaborations to advance drug discovery, particularly in glycoscience and cannabinoid research. Education: B.S. (Double First Class Honours) in Mathematics & Physics, University of New Brunswick, 1986 Graduate Diploma in Christian Studies, Regent College, Vancouver, 1996 Ph.D. in Chemistry, University of New Brunswick, 1998 (Advisor: Prof. Ajit Thakkar) Postdoctoral Fellow, UC Berkeley (with Prof. Martin Head-Gordon) Postdoctoral Fellow, University of Pennsylvania (with Prof. Michael Klein) Research Interests: Dr. Doerksen’s laboratory develops and applies computational medicinal chemistry approaches spanning chemoinformatics , molecular dynamics , virtual screening , and machine learning to understand how small molecules interact with proteins. Central themes include: Glycoscience : lectin–glycan interactions, glycosyltransferase regulation, glycomimetic design. Cannabinoids : CB1/CB2 receptor allosteric modulation, cannabidiol pharmacology, synthetic cannabinoid SAR. Neglected & Infectious Diseases : malaria, hepatitis B, tuberculosis, SARS-CoV-2, urinary-tract infections. Drug Delivery & Formulation : nanoparticle coatings, pharmacokinetic optimization, bioavailability enhancement. Publications Trend: Over 2023–2025 his 15 most recent papers reveal intense activity at the intersection of AI-driven discovery , glycobiology , and cannabinoid pharmacology , with emphasis on anti-infective, anticancer, and CNS-active agents. Key contributions include first-in-class MraY inhibitors for TB, cannabinoid-inspired antivirals against SARS-CoV-2, and glycomimetic antagonists of bacterial adhesins for UTI prevention. Scientific Awards & Honors: UM School of Pharmacy Faculty Service Award (2015–2016) UM School of Pharmacy Faculty Service Award (2010–2011) Editorial Boards: Molecules , AIMS Biophysics , Pharmaceutical Sciences , Perspectives in Medicinal Chemistry Repeated NIH, DoD, NSF, Wellcome Trust, and international grant-review panels (2010–present) Guest Editor for multiple special issues in Molecules and Frontiers journals Advising & Mentoring: As Associate Dean, Dr. Doerksen oversees University-wide graduate programs, chairs the Graduate Recruiting Fellowship and Scholarship Committee, and mentors students across disciplines. Faculty advisor for the UM chapters of the Christian Pharmacists Fellowship International (since 2005) and Taiwanese Student Association (2022–2025). He actively participates in PhD and MS thesis committees worldwide and has delivered NSF GRFP information sessions to support trainee funding. Laboratories & Teams: He directs research within the Computational Chemistry and Bioinformatics Research CORE (CCBRC) , fostering collaborative projects involving medicinal chemists, structural biologists, pharmacologists, and data scientists. The group leverages high-performance computing resources at the University of Mississippi to perform large-scale virtual screening, AI/ML model development, and integrative structural biology studies.
Rupali Rajendra Bhadane is a postdoctoral researcher at Åbo Akademi University's Pharmaceutical Science Laboratory (PSL) and Structural Bioinformatics Laboratory (SBL), contributing to interdisciplinary science under the Faculty of Natural Sciences and Technology. Her work spans computational biology, drug design, and sustainable material development. PhD in Pharmacy 8 years of undergraduate teaching experience Her research integrates virtual screening , molecular dynamics simulations , and DFT calculations to advance drug discovery (e.g., Glycomimetic SGLT2 inhibitors , HDAC-2 modulators ), while also applying computational methods to analyze bio-based adhesive materials and virus-mimetic nanoparticles . Recent publications highlight her work on Covid-19 spike protein mutations , g-quadruplex targeting , and core/shell nanostructures for siRNA delivery. She actively contributes to datasets through the Finnish National Protein Crystallography Consortium and European Synchrotron Radiation Facility . Current projects include D2V: From Dust to Value (2023-2026), focusing on circular bio-based residues with Business Finland funding. Her work aligns with UN SDGs for health innovation and environmental sustainability.
Peter Andreana is a Professor in the Department of Chemistry and Biochemistry at the University of Toledo's School of Green Chemistry and Engineering. His research focuses on carbohydrate chemistry, natural product synthesis, and vaccine development. Research areas include: Natural product synthesis of zwitterionic polysaccharides (ZPS) Diversity-oriented synthesis (DOS) for therapeutic agents Development of carbohydrate-based vaccines targeting MHCII pathways Combinatorial carbohydrate library creation Green chemistry applications in small molecule immunology studies The Andreana group investigates how carbohydrates modulate cellular functions through chemical approaches, with a particular interest in T-cell responses and immune pathway modulators. Their work connects organic chemistry with immunological applications through chemical genetics. Contact: peter.andreana@utoledo.edu | Office: WO 2232B, University of Toledo
Prof. Dr. Alexander Titz is a faculty member at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), affiliated with the Faculty of Natural Sciences and Technology. He holds the Professorship for Organic and Pharmaceutical Chemistry and leads an active research group focused on developing chemical agents against multi-resistant pathogens causing infectious diseases. His research spans several critical areas in medicinal chemistry, including: Synthesis of novel antibiotics and pathoblockers targeting resistant bacteria Development of carbohydrates and glycomimetics as therapeutic tools Biochemical and biophysical analysis of active ingredients and their target proteins Microbiological diagnostics, especially biofilm formation in Pseudomonas aeruginosa The research output reflects a strong interdisciplinary focus on drug discovery and chemical biology, particularly aimed at overcoming antimicrobial resistance. While specific publications are not listed, the thematic consistency suggests deep engagement in pharmaceutical sciences and synthetic organic chemistry. There are no listed scientific awards in the provided information. Prof. Titz advises research students as part of his group leadership, though specific names are not disclosed. There is no mention of external grants or funding sources in the available text. The research group maintains a dedicated website, indicating structured lab operations and team-based scientific inquiry.
Josipa Suć Sajko is a Researcher at the Ruđer Bošković Institute within the Division of Organic Chemistry and Biochemistry , specifically in the Synthetic Methodologies in Organic Chemistry laboratory. Her work focuses on organic synthesis, particularly involving multicomponent reactions, peptidomimetics, and the design of functional materials like organogelators. She has contributed to the development of self-healing materials, enzyme inhibitors, and glycomimetic libraries. Her research interests span synthetic organic chemistry, including the Ugi reaction, Passerini reaction, and asymmetric catalysis. She has explored applications in drug discovery, biomaterials, and biomolecular interactions, such as DNA/RNA binding by fluorescent peptides. Key areas include the synthesis of heterocyclic compounds, hydrazino derivatives, and enzyme-targeted therapeutics. Her publications demonstrate expertise in multicomponent synthesis, with notable contributions to γ-lactams, diazetidinones, and depsipeptides. She has also investigated anthrose-based biomimetic molecules and fluorophore-conjugated enzyme inhibitors. No scientific awards are explicitly listed in the provided materials. Her advising and grants are not detailed here, but her involvement in conferences and collaborative projects indicates active participation in academic networks. She is affiliated with the Department of Organic Chemistry and Biochemistry , contributing to both fundamental and applied research in organic chemistry.
Robert J. Doerksen is the Associate Dean of the Graduate School and a Professor of Medicinal Chemistry at the University of Mississippi's School of Pharmacy. He holds a dual role as a Research Professor in the Research Institute of Pharmaceutical Sciences. His research focuses on computational medicinal chemistry, glycoscience, cannabinoids, and natural products discovery. He earned a Double First Class Honours BSc in Mathematics and Physics from the University of New Brunswick (1986) and a PhD in Chemistry from the same institution (1998). His postdoctoral training included studies at UC Berkeley and the University of Pennsylvania. Doerksen's research emphasizes computational methods to study protein-ligand interactions, glycobiology, and drug design for diseases like Alzheimer’s, malaria, and cancer. He leads the Computational Chemistry and Bioinformatics Research Center (CCBRC) within the NIH-funded GlyCORE Center of Research Excellence (GM130460). His work integrates molecular modeling, QSAR analysis, and collaborative natural product chemistry to develop novel therapeutic agents. Key research areas include: 1) Glycoscience: glycan-protein interactions and glycoprotein bioinformatics; 2) Cannabinoid receptor modulation for neuroinflammation and pain management; 3) Antimalarial and antituberculosis drug discovery; 4) Delivery systems using cyclodextrins and responsive nanoparticles. His lab has pioneered computational tools for drug discovery, including docking algorithms and QSAR modeling. Doerksen has secured over $10 million in NIH funding, including multi-PI leadership roles in GlyCORE and NSF REU programs. He advises students in computational chemistry and medicinal chemistry, contributing to over 200 peer-reviewed publications. His lab collaborates extensively with chemists, biologists, and clinicians to translate computational insights into experimental drug candidates.
Dr. Brett Schwartz is a Senior Research Fellow at the Research School of Chemistry , Australian National University , with expertise in organic chemistry, biochemistry, and chemical synthesis. He has collaborated extensively on projects related to enzymatic interactions, peptide modification, and heparanase inhibition. PhD from University of Queensland (UQ) Research Interests: His work spans enzymology, glycobiology, and medicinal chemistry, focusing on: Nicotinamide cofactor biomimetics and alcohol dehydrogenase activity Development of glycomimetics for heparanase inhibition Peptide synthesis and sulfated xylooligosaccharide conformational analysis Bicyclobutane-triazolinedione cycloadditions for molecular engineering Recent Publication Trends: Over the last five years, his research has emphasized therapeutic glycomimetics (heparanase inhibitors), peptide sulfation strategies, and chemical synthesis innovations using cycloadditions. Collaborative Projects: He is actively involved in international collaborations and has contributed to projects involving: High-pressure chemical synthesis reactors Supercritical fluid chromatography for enantiopurity analysis Commercialization of heparanase inhibitors through Beta Therapeutics
R.N. Bhadane is a Postdoctoral Researcher at the Faculty of Science and Engineering , Åbo Akademi University , with affiliations to the Pharmaceutical Science Laboratory (PSL) and Structural Bioinformatics Laboratory (SBL) . Bhadane holds a PhD in Pharmacy and has 8 years of undergraduate teaching experience. Research focuses span drug design, molecular dynamics simulations, protein science, and nanotechnology. Expertise: Virtual screening, chemoinformatics, protein-ligand dynamics, nanoparticle fabrication, and sustainable development goals. Collaborations: Extensive work with the Finnish National Protein Crystallography Consortium and European Synchrotron Radiation Facility. Research Themes: Bhadane’s work integrates computational and experimental approaches, including in silico drug discovery, glycomimetics, and sustainable healthcare solutions. Key areas involve SARS-CoV-2 spike protein mutations, siRNA delivery systems, and HDAC-2 modulation in diabetes-related renal injury. Recent Publications: 2024 studies on aptamer-DNAzyme frameworks for gastric cancer, SGLT2 inhibitors, and HDAC-2 in diabetic nephropathy; 2022 work on Omicron variant binding energy calculations and virus-mimetic nanoparticles for siRNA delivery.
Dr. John Southern is an Assistant Professor in the Department of Chemistry at Trinity College Dublin (TCD), where he conducts research at the intersection of organic, medicinal, and chemical biology. His work focuses on the synthesis of novel nucleobase analogs and small molecules with therapeutic potential for autoimmune and neuroinflammatory diseases. Assistant Professor, Department of Chemistry, Trinity College Dublin Visiting Professor, Louvain-la-Neuve University, Belgium (2006) His research interests include medicinal chemistry, tRNA modification, autoimmune disease modulation, and synthetic methodology development. He has pioneered work on artificial nucleobase incorporation into tRNA, demonstrating disease remission in animal models of multiple sclerosis. His group designs bioactive heterocycles, including thiophenes, pyrrolidines, and piperidines, with applications in immunology and neuroscience. The recent publications highlight a strong trend toward developing novel agents for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis. These studies combine synthetic organic chemistry with biological evaluation, focusing on cytokine regulation (e.g., IL-6), tRNA modification enzymes, and neuroinflammatory pathways. The work bridges chemical synthesis and translational medicine, aiming to deliver new therapeutic strategies through nucleic acid and small molecule interventions. Scientific Awards and Honors: Visiting Professor, University of Louvain-la-Neuve, Belgium (Jan–Apr 2006) Dr. Southern has advised several graduate students and postdoctoral researchers, though specific names are not listed in the source material. His research has been supported by peer-reviewed grants, particularly in the areas of autoimmune disease therapeutics and nucleic acid chemistry, although grant details are not specified. He collaborates closely with researchers such as Prof. Stephen J. Connon and Prof. Vincent P. Kelly. While no dedicated laboratory name is mentioned, his research group operates within the School of Chemistry at TCD, contributing to the institution’s strengths in pharmaceutical and synthetic chemistry. The team employs techniques in organic synthesis, enzymology, and molecular biology to explore novel biochemical interventions.
Dr. Robert de Vries is an Associate Professor at the Department of Chemical Biology and Drug Discovery , Utrecht Institute for Pharmaceutical Sciences , Utrecht University. His research focuses on the receptor binding specificity of influenza A viruses and other glycan-binding pathogens, with particular interest in mechanistic understanding of viral-host interactions , chemo-enzymatic glycan synthesis , and development of glycan arrays for specificity assays. His work has revealed key mutations in zoonotic influenza viruses through collaborations with structural biology groups (Ian Wilson, Rob Woods), combining X-ray crystallography , glycan modeling , and multivalent binding assays . He has received prestigious grants including an ERC Starting Grant (2018) , NWO VENI Fellowship , and Rubicon Fellowship . Key Research Themes: Influenza A virus receptor specificity Rotavirus and avian coronavirus glycan interactions Antiviral glycomimetics development Host sialic acid diversity in pathogenesis Notable Discoveries: Molecular basis for avian-human receptor switching in H5/H7 viruses Role of sialylated glycolipids in SARS-CoV-2 entry Evolutionary constraints in hemagglutinin glycosylation Novel influenza receptors in livestock species Scientific Recognition: Beijerinck Premium (2019) ESWI Best Body of Work Award (2020) ERC Proof of Concept Grants (2022, 2024) Mizutani Foundation Grant (2023) NWO XL Grant (2024) He supervises PhD students and collaborates with international institutions like Scripps Research Institute and University of Twente , with recent publications in Nature , PNAS , and Cell journals.
